We heard about the interesting roles that mitochondrial dysfunction and the gastrointestinal microbiome play in Parkinson’s disease, thanks to expert insight from MDS Congress Scientific Program Committee member, Carolyn Sue (Kolling Institute, University of Sydney, Northern Clinical School; and Royal North Shore Hospital, St Leonards, New South Wales, Australia).
1. Please describe the significance of mitochondrial dysfunction in relation to the pathology of Parkinson’s disease (PD). (0:05)
2. In addition to mitochondrial dysfunction, there has been increasing interest in the gastrointestinal microbiome (GM) in PD. What do we currently know about the role of the GM in PD? (1:25)
3. How might our increased understanding of mitochondrial dysfunction and the GM in PD contribute to novel therapeutics? (2:22)
Speaker disclosure: Carolyn Sue has nothing relevant to disclose in relation to this video interview.
Filmed at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), Nice, France, September 2019.
Share this Video
Related Videos In Parkinson's Disease
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!